Multiplex targeted proteomic assay for biomarker detection in plasma: a pancreatic cancer biomarker case study.

Biomarkers are most frequently proteins that are measured in the blood. Their development largely relies on antibody creation to test the protein candidate performance in blood samples of diseased versus nondiseased patients. The creation of such antibody assays has been a bottleneck in biomarker progress due to the cost, extensive time, and effort required to complete the task. Targeted proteomics is an emerging technology that is playing an increasingly important role to facilitate disease biomarker development. In this study, we applied a SRM-based targeted proteomics platform to directly detect candidate biomarker proteins in plasma to evaluate their clinical utility for pancreatic cancer detection. The characterization of these protein candidates used a clinically well-characterized cohort that included plasma samples from patients with pancreatic cancer, chronic pancreatitis, and healthy age-matched controls. Three of the five candidate proteins, including gelsolin, lumican, and tissue inhibitor of metalloproteinase 1, demonstrated an AUC value greater than 0.75 in distinguishing pancreatic cancer from the controls. In addition, we provide an analysis of the reproducibility, accuracy, and robustness of the SRM-based proteomics platform. This information addresses important technical issues that could aid in the adoption of the targeted proteomics platform for practical clinical utility.

[1]  Brendan MacLean,et al.  Bioinformatics Applications Note Gene Expression Skyline: an Open Source Document Editor for Creating and Analyzing Targeted Proteomics Experiments , 2022 .

[2]  N Urban,et al.  Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. , 2004, Gynecologic oncology.

[3]  R. Aebersold,et al.  High Sensitivity Detection of Plasma Proteins by Multiple Reaction Monitoring of N-Glycosites*S , 2007, Molecular & Cellular Proteomics.

[4]  Margaret Sullivan Pepe,et al.  Standardizing Diagnostic Markers to Evaluate and Compare Their Performance , 2005, Epidemiology.

[5]  A. Pandey,et al.  Molecular alterations in exocrine neoplasms of the pancreas. , 2009, Archives of pathology & laboratory medicine.

[6]  S. Hanash,et al.  A Compendium of Potential Biomarkers of Pancreatic Cancer , 2009, PLoS medicine.

[7]  Damon H. May,et al.  Pilot Study of Blood Biomarker Candidates for Detection of Pancreatic Cancer , 2010, Pancreas.

[8]  William E Grizzle,et al.  Serum Biomarker Panels for the Detection of Pancreatic Cancer , 2011, Clinical Cancer Research.

[9]  R. Brand.  The diagnosis of pancreatic cancer. , 2001, Cancer journal.

[10]  R. Aebersold,et al.  Quantitative proteomics investigation of pancreatic intraepithelial neoplasia , 2009, Electrophoresis.

[11]  Ruedi Aebersold,et al.  Pancreatic cancer proteome: the proteins that underlie invasion, metastasis, and immunologic escape. , 2005, Gastroenterology.

[12]  Henry H. N. Lam,et al.  PeptideAtlas: a resource for target selection for emerging targeted proteomics workflows , 2008, EMBO reports.

[13]  T. Stevens,et al.  Combined Endoscopic Ultrasound and Secretin Endoscopic Pancreatic Function Test in Patients Evaluated for Chronic Pancreatitis , 2010, Digestive Diseases and Sciences.

[14]  Ruedi Aebersold,et al.  Quantitative Proteomics Analysis Reveals That Proteins Differentially Expressed in Chronic Pancreatitis Are Also Frequently Involved in Pancreatic Cancer*S , 2007, Molecular & Cellular Proteomics.

[15]  T. Veenstra,et al.  Targeted proteomics for validation of biomarkers in clinical samples. , 2009, Briefings in functional genomics & proteomics.

[16]  A. Andrén-sandberg,et al.  Pancreatitis and the risk of pancreatic cancer , 1993 .

[17]  Darryl B. Hardie,et al.  Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). , 2004, Journal of proteome research.

[18]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[19]  Troels Z. Kristiansen,et al.  Biomarker Discovery from Pancreatic Cancer Secretome Using a Differential Proteomic Approach*S , 2006, Molecular & Cellular Proteomics.

[20]  Pei Wang,et al.  A targeted proteomics–based pipeline for verification of biomarkers in plasma , 2011, Nature Biotechnology.

[21]  Christoph H Borchers,et al.  Multi-site assessment of the precision and reproducibility of multiple reaction monitoring–based measurements of proteins in plasma , 2009, Nature Biotechnology.

[22]  P. Ruszniewski,et al.  Risk of pancreatic adenocarcinoma in chronic pancreatitis , 2002, Gut.

[23]  R. Aebersold,et al.  mProphet: automated data processing and statistical validation for large-scale SRM experiments , 2011, Nature Methods.

[24]  Gilbert S Omenn,et al.  THE HUPO Human Plasma Proteome Project , 2007, Proteomics. Clinical applications.

[25]  Y. L. Ramachandra,et al.  Human Proteinpedia enables sharing of human protein data , 2008, Nature Biotechnology.

[26]  Ruedi Aebersold,et al.  Mass spectrometry based targeted protein quantification: methods and applications. , 2009, Journal of proteome research.

[27]  G. Sandblom,et al.  TPS, CA 19-9, VEGF-A, and CEA as Diagnostic and Prognostic Factors in Patients with Mass Lesions in the Pancreatic Head , 2008, Upsala journal of medical sciences.

[28]  Ruedi Aebersold,et al.  On the development of plasma protein biomarkers. , 2011, Journal of proteome research.

[29]  N. Kitteringham,et al.  Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[30]  Damon H. May,et al.  Protein alterations associated with pancreatic cancer and chronic pancreatitis found in human plasma using global quantitative proteomics profiling. , 2011, Journal of proteome research.

[31]  Lennart Martens,et al.  PRIDE: a public repository of protein and peptide identifications for the proteomics community , 2005, Nucleic Acids Res..

[32]  S. Gerber,et al.  Absolute quantification of protein and post-translational modification abundance with stable isotope–labeled synthetic peptides , 2011, Nature Protocols.

[33]  Ruedi Aebersold,et al.  Targeted proteomic strategy for clinical biomarker discovery , 2009, Molecular oncology.

[34]  Michelle A. Anderson,et al.  A Mouse to Human Search for Plasma Proteome Changes Associated with Pancreatic Tumor Development , 2008, PLoS medicine.

[35]  P. Brown,et al.  Systematic Evaluation of Candidate Blood Markers for Detecting Ovarian Cancer , 2008, PloS one.

[36]  C. Logsdon,et al.  Progress on molecular markers of pancreatic cancer , 2007, Current opinion in gastroenterology.

[37]  Leigh Anderson,et al.  Quantitative Mass Spectrometric Multiple Reaction Monitoring Assays for Major Plasma Proteins* , 2006, Molecular & Cellular Proteomics.

[38]  S. Carr,et al.  Quantitative, Multiplexed Assays for Low Abundance Proteins in Plasma by Targeted Mass Spectrometry and Stable Isotope Dilution*S , 2007, Molecular & Cellular Proteomics.